Eyenovia获得了5000万美元的私人位置，任命新的CIO，并使用Hype Sigkens潜入加密货币。这是生物技术的未来吗？

Eyenovia's Bold Leap: Private Placement Fuels Crypto Treasury and New CIO

Eyenovia的Bold Leap：私人位置燃料加密货币和新CIO

Eyenovia is making waves with a $50 million private placement, a new Chief Investment Officer, and a foray into cryptocurrency. Let's dive into what this means for the company and its investors.

Eyenovia正在以5000万美元的私人位置，新的首席投资官以及对加密货币的尝试。让我们深入了解这对公司及其投资者意味着什么。

Eyenovia Secures $50 Million Private Placement

Eyenovia获得了5000万美元的私人安置

On June 17, 2025, Eyenovia announced the closing of a $50 million private placement with institutional investors. This substantial funding is earmarked for building a treasury reserve of HYPE tokens, the native currency of the Hyperliquid blockchain. It is strategic move, positioning Eyenovia at the intersection of biotech and digital finance.

2025年6月17日，Eyenovia宣布关闭了与机构投资者的5000万美元私人安置。这笔可观的资金专门用于建立高流利区块链的原始货币的炒作代币储备。这是战略性的举动，将Eyenovia定位在生物技术和数字融资的交汇处。

New CIO and Crypto Strategy

新的CIO和加密策略

Hyunsu Jung has been appointed as Chief Investment Officer and Board Member, signaling Eyenovia's serious commitment to its new cryptocurrency treasury strategy. According to Eyenovia, this initiative aims to unlock long-term value for shareholders by capitalizing on the growing adoption of digital currencies. Jung stated that the purchase of HYPE tokens paves the way for deeper engagement in the Hyperliquid ecosystem.

Hyunsu Jung被任命为首席投资官兼董事会成员，这表明Eyenovia对其新的加密货币国库策略的认真承诺。根据Eyenovia的说法，该计划旨在通过利用日益增长的数字货币来利用股东的长期价值。荣格说，购买炒作令牌为更深入的生态系统铺平了道路。

Optejet Development on Track

optejet开发在正轨上

While venturing into the crypto world, Eyenovia remains focused on its core business: ophthalmic technology. The development of the Gen-2 Optejet User Filled Device (UFD) is progressing as planned, with FDA registration targeted for September 2025. Eyenovia is also exploring partnerships for the device, initially focusing on applications like OTC lens rewetting and artificial tears. The Optejet UFD could make eye treatments easier and safer, helping people stick to their care routines.

在进入加密货币世界时，Eyenovia仍然专注于其核心业务：眼科技术。 Gen-2 OpteJet用户填充设备（UFD）的开发正在按计划进行，FDA注册针对2025年9月。Eyenovia还在探索该设备的合作伙伴关系，最初着重于OTC Lens Rens Rens Rewetting和人工眼泪等应用。 OpteJet UFD可以使眼睛治疗更加轻松，更安全，从而帮助人们坚持他们的护理程序。

Eyenovia Eyes Rebrand as HYPE Investment Strategy Expands

Eyenovia Eyes Rebrand随着炒作投资策略的扩展

Pending Board approval, Eyenovia is expected to change its name and ticker to “Hyperion DeFi” and “HYPD,” respectively, reflecting its new focus on both eye care and digital finance. This rebranding underscores the company's vision of blending eye care innovation with Web3.

董事会批准，Eyenovia有望将其名称和股票更改为“ Hyperion Defi”和“ Hypd”，这反映了其对眼部护理和数字融资的新关注。这种重塑强调了该公司将眼保健创新与Web3融合的愿景。

The Downside?

缺点？

Not everyone is bullish on Eyenovia's prospects. TipRanks’ AI Analyst, Spark, rates EYEN as an Underperform, citing poor financial performance, significant operational losses, and a weak balance sheet. Spark’s analysis notes that while there is revenue growth, the negative equity and insufficient cash flow generation are critical risks. Technical indicators also point to a bearish trend, and the valuation metrics are unappealing due to a negative P/E ratio and absence of dividends.

并非每个人都看好Eyenovia的前景。 Tipranks的AI分析师Spark，将Eyen评为表现不佳，理由是财务绩效不佳，运营损失巨大和资产负债表薄弱。 Spark的分析指出，尽管收入增长，但负股权和现金流量不足是关键风险。技术指标还指出了看跌趋势，由于市盈率负和股息的缺乏，估值指标却没有吸引力。

Final Thoughts

最后的想法

Eyenovia's bold move into cryptocurrency is certainly a conversation starter. While the company faces financial headwinds, its innovative spirit and strategic shift could pave the way for future growth. Whether it's a stroke of genius or a risky gamble remains to be seen, but one thing's for sure: Eyenovia is not afraid to shake things up. Will they make it rain HYPE? Only time will tell!

Eyenovia大胆进入加密货币的行动无疑是对话的开始。尽管该公司面临财务逆风，但其创新精神和战略转变可能为未来的增长铺平道路。无论是天才还是冒险的赌博，还有待观察，但可以肯定的是：Eyenovia不怕摇动一切。他们会让下雨炒作吗？只有时间会证明！